Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
119 Results for "
MST
" in MedChemExpress (MCE) Product Catalog:
Products (119)
119 Results for "MST" in MCE Product Catalog:
Cat. No.: HY-N20645
Category:
Target:
Cat. No.: HY-180900
CAS No.: 2249005-28-3
Target:
Research Areas:
Z3071585108 is a small molecule binder of the LAG-3 D1 domain with Kd values measured for the MST-TRIC channel and spectral shift detection of 59.2 and 56.1 μM respectively. Z3071585108 partially inhibits the binding of LAG-3 to MHCII, with an EC₅₀ of 42.9 μM. Z3071585108 can be used for the study of small molecule immunotherapies targeting LAG-3 .
Cat. No.: HY-181685
Target:
Research Areas:
LAGi-DEL is a LAG-3 inhibitor, with Kd values of 97.33 nM and 271 nM in surface plasmon resonance (SPR) assay and microscale thermophoresis (MST) assay, respectively. LAGi-DEL blocks the LAG-3/MHC-II interaction, with an EC50 of 138 nM. LAGi-DEL restores T cell activation, enhances IFN-γ secretion and promotes immune-mediated cytotoxicity. LAGi-DEL can be used in the research of acute myeloid leukemia, lung cancer and melanoma .
Cat. No.: HY-N20697
Category:
Target:
Cat. No.: HY-181079
CAS No.: 2667022-87-7
Research Areas:
RANKL-IN-2 is an orally active RANKL inhibitor with Kd values of 3.21 μM and 4.625 μM in the SPR and MST assays, respectively. RANKL-IN-2 binds to RANKL to interfere with RANKL-RANK interaction. RANKL-IN-2 suppresses osteoclastogenesis by inhibiting ROS, MAPK and NF-κB pathways. RANKL-IN-2 inhibits osteoclastogenesis via inhibition of RANKL-induced osteoclast formation, bone resorption, and osteoclast-specific gene and protein expressions in vitro.RANKL-IN-2 prevents bone loss in ovariectomized osteoporosis mice.RANKL-IN-2 can be used for the research of osteoporosis .
Cat. No.: HY-184449
Research Areas:
PHGDH-IN-7 is an orally active Cys281-targeted covalent noncompetitive PHGDH inhibitor with an enzymatic IC50 of 0.8 μM, MST Kd of 3.4 μM, and Ki of 2.82 μM. PHGDH-IN-7 disrupts PHGDH homodimer formation. PHGDH-IN-7 blocks cellular de novo serine synthesis. PHGDH-IN-7 elevates intracellular ROS levels and inhibits DNA replication. PHGDH-IN-7 resensitizes EGFR-TKI-resistant lung adenocarcinoma cells. PHGDH-IN-7 suppresses triple-negative breast tumor growth with no obvious systemic toxicity. PHGDH-IN-7 serves as a tool compound for PHGDH-dependent tumor research .
Cat. No.: HY-P81384A
Synonyms: MST1R; PTK8; RON; Macrophage-stimulating protein receptor; MSP receptor; CDw136; Protein-tyrosine kinase 8; p185-Ron; CD136
Cat. No.: HY-P70113
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CLIC5; Chloride Intracellular Channel Protein; Chloride Intracellular Channel 5; CLIC5 Protein; DFNB102; DFNB103; Chloride Intracellular Channel Protein 5; MSTP130; Glutaredoxin-Like Oxidoreductase CLIC5; MST130
Species:
Human
Source:
E. coli
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
